XTX Topco’s Minerva Neurosciences NERV Stock Holding History

XTX Topco’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,275	Closed	-$79K	–	935
2021 Q2	$79K	Buy	+4,275	New	+$92K	0.03%	686

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

XTX Topco's NERV Position: Q3 2021 in Review

XTX Topco sold out of Minerva Neurosciences (NERV) in Q3 2021, closing a stake of 4,275 shares — an estimated $79K sold.

XTX Topco first reported a position in NERV in Q2 2021 and held it in 1 quarter. The position peaked at $79K in Q2 2021. 46 funds tracked by Wall St. Rank hold NERV as of Q3 2021.

XTX Topco reported no remaining Minerva Neurosciences position as of Q3 2021 after selling out during the quarter.
XTX Topco sold 4,275 Minerva Neurosciences shares in Q3 2021, an estimated $79K.
XTX Topco first reported a position in Minerva Neurosciences in Q2 2021 and held it in 1 quarter.
XTX Topco's Minerva Neurosciences position peaked at $79K in Q2 2021.
46 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q3 2021.

Based on XTX Topco's 13F filing for Q3 2021, filed 12 Nov 2021.